Literature DB >> 19745687

Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects.

Evangelia Baimpa1, Issa J Dahabreh, Michael Voulgarelis, Haralampos M Moutsopoulos.   

Abstract

The diverse hematologic manifestations of primary Sjögren syndrome (pSS) have not been systematically investigated, and their prognostic relevance remains unclear. We conducted a retrospective study of 536 consecutive patients followed in our institution to assess the prevalence of hematologic abnormalities and their associations with various disease manifestations in pSS. We also aimed to identify risk factors for the development of non-Hodgkin lymphoma (NHL) overall and by subtype. Anemia of chronic disease and hypergammaglobulinemia were the most prevalent hematologic manifestations encountered at diagnosis and during the course of pSS. Univariate analysis between cytopenias and glandular manifestations revealed a statistically significant correlation between lymphocytopenia and parotid gland enlargement (p = 0.002), as well as between neutropenia and xerostomia (p = 0.019). Anemia, lymphocytopenia, thrombocytopenia, hypergammaglobulinemia, the presence of monoclonal serum proteins, and cryoglobulinemia correlated significantly with the presence of extraglandular symptoms such as palpable purpura, lymphadenopathy, and splenomegaly. Lymphoma was diagnosed in 7.5% (95% confidence interval [CI], 5.4%-10%) of patients. Marginal zone B-cell lymphomas (MZBCLs) were the predominant histologic type (65%; 95% CI, 48.3%-79.4%), while diffuse large B-cell lymphomas (DLBCLs) accounted for 17.5% (95% CI, 7.3%-32.8%) of all cases. The development of NHL in patients with pSS could be predicted by the presence of simple clinical and laboratory factors at diagnosis: neutropenia (p = 0.041), cryoglobulinemia (p = 0.008), splenomegaly (p = 0.006), lymphadenopathy (p = 0.021), and low C4 levels (p = 0.009). Patients carrying any of these factors had a more than 5-fold increased risk of NHL compared to patients with no risk factors at all. The above set of disease characteristics could predict subsequent development of MZBCL; the presence of lymphocytopenia (p = 0.044) at diagnosis served as a risk factor for the development of a non-MZBCL, most commonly DLBCL. Anemia of chronic disease and hypergammaglobulinemia are common hematologic manifestations at diagnosis and during the course of pSS. Neutropenia and cryoglobulinemia at diagnosis are significantly associated with an increased risk of lymphoma development.

Entities:  

Mesh:

Year:  2009        PMID: 19745687     DOI: 10.1097/MD.0b013e3181b76ab5

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  52 in total

1.  Biomarkers. Saliva proteomics is a promising tool to study Sjögren syndrome.

Authors:  Athanasios G Tzioufas; Efstathia K Kapsogeorgou
Journal:  Nat Rev Rheumatol       Date:  2015-02-10       Impact factor: 20.543

Review 2.  Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature.

Authors:  Vadim Romanovich Gorodetskiy; Natalya Alexandrovna Probatova; Stefka Gospodinova Radenska-Lopovok; Natalya Valerievna Ryzhikova; Yulia Vladimirovna Sidorova; Andrey Borisovich Sudarikov
Journal:  Rheumatol Int       Date:  2019-11-09       Impact factor: 2.631

3.  Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation.

Authors:  D Saadoun; B Terrier; J Bannock; T Vazquez; C Massad; I Kang; F Joly; M Rosenzwajg; D Sene; P Benech; L Musset; D Klatzmann; E Meffre; P Cacoub
Journal:  Arthritis Rheum       Date:  2013-04

Review 4.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

Review 5.  Update on Pathogenesis of Sjogren's Syndrome.

Authors:  Pulukool Sandhya; Biji Theyilamannil Kurien; Debashish Danda; Robert Hal Scofield
Journal:  Curr Rheumatol Rev       Date:  2017

Review 6.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

Review 7.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

8.  Malignancy risk in Korean male patients with ankylosing spondylitis.

Authors:  Bora Nam; Hyoungyoung Kim; Eun Jin Jang; Soo-Kyung Cho; Yoon-Kyoung Sung; Tae-Hwan Kim
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

9.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12

10.  Pain severity and neuropathic pain symptoms in primary Sjögren's syndrome: a comparison study of seropositive and seronegative Sjögren's syndrome patients.

Authors:  Barbara M Segal; Brian Pogatchnik; Lisa Henn; Kyle Rudser; Kathy Moser Sivils
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-08       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.